GALR1
Galanin receptor type 1
Also known as: GALNR, GALNR1, GALR1_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P47211
- Gene
- GALR1
- Ensembl
- ENSG00000166573
- Chromosome
- 18
- Canonical length
- 349 aa
- Protein class
- G-protein coupled receptors, Predicted membrane proteins
- Subcellular location
- Plasma membrane
OverviewNCBI Gene
The neuropeptide galanin elicits a range of biological effects by interaction with specific G-protein-coupled receptors. Galanin receptors are seven-transmembrane proteins shown to activate a variety of intracellular second-messenger pathways. GALR1 inhibits adenylyl cyclase via a G protein of the Gi/Go family. GALR1 is widely expressed in the brain and spinal cord, as well as in peripheral sites such as the small intestine and heart. [provided by RefSeq, Jul 2008]
Canonical amino-acid sequenceUniProt
349 residues, UniProt reviewed canonical sequence.
>P47211|GALR1
1 MELAVGNLSE GNASWPEPPA PEPGPLFGIG VENFVTLVVF GLIFALGVLG NSLVITVLAR
61 SKPGKPRSTT NLFILNLSIA DLAYLLFCIP FQATVYALPT WVLGAFICKF IHYFFTVSML
121 VSIFTLAAMS VDRYVAIVHS RRSSSLRVSR NALLGVGCIW ALSIAMASPV AYHQGLFHPR
181 ASNQTFCWEQ WPDPRHKKAY VVCTFVFGYL LPLLLICFCY AKVLNHLHKK LKNMSKKSEA
241 SKKKTAQTVL VVVVVFGISW LPHHIIHLWA EFGVFPLTPA SFLFRITAHC LAYSNSSVNP
301 IIYAFLSENF RKAYKQVFKC HIRKDSHLSD TKESKSRIDT PPSTNCTHVLocalizationUniProt · AlphaFold · HPA
Whether an antibody against GALR1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 7
- Mean surface accessibility (rSASA)
- 0.34
- Highest tissue expression
- 1.4 nTPM
Expression across tissuesHPA
Tissue
- adrenal gland: 1.4 nTPM
- pituitary gland: 1.3 nTPM
- cerebral cortex: 0.8 nTPM
- hypothalamus: 0.7 nTPM
- retina: 0.5 nTPM
- amygdala: 0.4 nTPM
Single-cell type
- pituitary stem cells: 578 nCPM
- adrenal medulla cells: 96 nCPM
- oligodendrocyte progenitor cells: 92 nCPM
- early spermatids: 71 nCPM
- late primary spermatocytes: 41 nCPM
- neuroendocrine cells: 34 nCPM
Immune cell
- basophil: 0.1 nTPM
- neutrophil: 0.1 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
- intermediate monocyte: 0 nTPM
Brain region
- hypothalamus: 6.3 nTPM
- midbrain: 5.7 nTPM
- spinal cord: 5.1 nTPM
- medulla oblongata: 4.7 nTPM
- thalamus: 4.4 nTPM
- cerebral cortex: 4 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.35
- gnomAD pLI
- 0
- gnomAD missense Z
- -0.21
- DepMap mean gene effect
- 0.09
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- adenylate cyclase-activating G protein-coupled receptor signaling pathway
- negative regulation of adenylate cyclase activity
- neuropeptide signaling pathway
- positive regulation of cortisol secretion
- positive regulation of cytosolic calcium ion concentration
- positive regulation of transcription by RNA polymerase II
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of GALR1 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads GALR1 as an antibody target. Whether an autoantibody or antibody against GALR1 could matter depends on whether native GALR1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
GALR1 is annotated at the cell surface, where native GALR1 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label GALR1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...